TECH · Healthcare
BIO-TECHNE CORP
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
39
Congress
0
Insiders
50
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$11.2B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About BIO-TECHNE CORP
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This…
Who's behind the signal
Every informed buyer we can see on TECH, across all three feeds.
Hedge funds · 7
Durable Capital (Ellenbogen)
Increased +50%
Glenview Capital Mgmt (Robbins)
Increased +66%
Citadel Advisors
Increased +299%
AQR Capital Management
Increased +42%
Tudor Investment (Paul Tudor Jones)
Decreased −15%
Gotham Asset Mgmt (Greenblatt)
Decreased −18%
+1 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
BIO-TECHNE CORP isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
7
Investors
0
New positions
4
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.3×
% of portfolio
1.2%
Position change
+50%
1.2% of Durable Capital's portfolio
Trust weight: 1.2×
% of portfolio
0.8%
Position change
+66%
0.8% of Glenview Capital Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+299%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+42%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.2×
% of portfolio
0.1%
Position change
−15%
0.1% of Tudor Investment's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−18%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−92%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to BIO-TECHNE CORP
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell BIO-TECHNE CORP or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime